Blockade of programmed death-1/programmed death ligand pathway enhances the antitumor immunity of human invariant natural killer T cells

The role of invariant natural killer T (iNKT) cells in antitumor immunity has been studied extensively, and clinical trials in patients with advanced cancer have revealed a prolonged survival in some cases. In recent years, humanized blocking antibodies against co-stimulatory molecules such as PD-1...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Cancer Immunol Immunother
Egile Nagusiak: Kamata, Toshiko, Suzuki, Akane, Mise, Naoko, Ihara, Fumie, Takami, Mariko, Makita, Yuji, Horinaka, Atsushi, Harada, Kazuaki, Kunii, Naoki, Yoshida, Shigetoshi, Yoshino, Ichiro, Nakayama, Toshinori, Motohashi, Shinichiro
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Springer Berlin Heidelberg 2016
Gaiak:
Original Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5099366/
https://ncbi.nlm.nih.gov/pubmed/27631416
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00262-016-1901-y
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak